Literature DB >> 35927602

Current antihypertensive treatment and treatment-resistant hypertension in Japanese patients with chronic kidney disease.

Akihiro Tsuchimoto1, Shigeru Tanaka1, Hiromasa Kitamura1, Hiroto Hiyamuta1,2, Kazuhiko Tsuruya1,3, Takanari Kitazono1, Toshiaki Nakano4.   

Abstract

BACKGROUND: Hypertension is an important prognostic predictor in patients with chronic kidney disease (CKD), and the recommended target blood pressure has been continuously revised. This study aimed to reveal the current antihypertensive practices in Japanese patients with CKD.
METHODS: In the Fukuoka Kidney disease Registry, we extracted 3664 non-dialysis-dependent patients with CKD. Apparent treatment-resistant hypertension (aTRH) was defined as a failure of blood-pressure control treated with three antihypertensive medication classes or a treatment with ≥ 4 classes regardless of blood pressure. The blood-pressure control complied with the target blood pressure recommended by the KDIGO 2012 guideline.
RESULTS: The median age of the patients was 67 years, body mass index (BMI) was 23 kg/m2, and estimated glomerular filtration rate (eGFR) was 40 mL/min/1.73 m2. The number of patients with unachieved blood-pressure control was 1933, of whom 26% received ≥ 3 classes of antihypertensive medications. The first choice of medication was renin-angiotensin system inhibitors, followed by calcium-channel blockers. The rate of thiazide use was low in all CKD stages (3-11%). The prevalence of aTRH was 16%, which was significantly associated with BMI (odds ratio [95% confidence interval] per 1-standard deviation change, 1.38 [1.25-1.53]), decreased eGFR (1.87 [1.57-2.23]), as well as age, diabetes mellitus, and chronic heart disease.
CONCLUSIONS: Renal dysfunction and obesity are important risk factors of aTRH. Even under nephrologist care, most patients were treated with insufficient antihypertensive medications. It is important to prescribe sufficient classes of antihypertensive medications, including diuretics, and to improve patients' lifestyle habits.
© 2022. The Author(s), under exclusive licence to The Japanese Society of Nephrology.

Entities:  

Keywords:  Cardiovascular disease; Chronic kidney disease; Clinical inertia; Diuretics; Polypharmacy; Uncontrolled hypertension

Mesh:

Substances:

Year:  2022        PMID: 35927602     DOI: 10.1007/s10157-022-02250-9

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.617


  28 in total

1.  Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study.

Authors:  K Yamagata; K Ishida; T Sairenchi; H Takahashi; S Ohba; T Shiigai; M Narita; A Koyama
Journal:  Kidney Int       Date:  2006-11-22       Impact factor: 10.612

2.  Prevalence and Prognostic Significance of Apparent Treatment Resistant Hypertension in Chronic Kidney Disease: Report From the Chronic Renal Insufficiency Cohort Study.

Authors:  George Thomas; Dawei Xie; Hsiang-Yu Chen; Amanda H Anderson; Lawrence J Appel; Shirisha Bodana; Carolyn S Brecklin; Paul Drawz; John M Flack; Edgar R Miller; Susan P Steigerwalt; Raymond R Townsend; Matthew R Weir; Jackson T Wright; Mahboob Rahman
Journal:  Hypertension       Date:  2015-12-28       Impact factor: 10.190

3.  Blood pressure predicts risk of developing end-stage renal disease in men and women.

Authors:  Masahiko Tozawa; Kunitoshi Iseki; Chiho Iseki; Kozen Kinjo; Yoshiharu Ikemiya; Shuichi Takishita
Journal:  Hypertension       Date:  2003-04-21       Impact factor: 10.190

4.  Pre-hypertension as a significant predictor of chronic kidney disease in a general population: the Ohasama Study.

Authors:  Atsuhiro Kanno; Masahiro Kikuya; Takayoshi Ohkubo; Takanao Hashimoto; Michihiro Satoh; Takuo Hirose; Taku Obara; Hirohito Metoki; Ryusuke Inoue; Kei Asayama; Yoh Shishido; Haruhisa Hoshi; Masaaki Nakayama; Kazuhito Totsune; Hiroshi Satoh; Hiroshi Sato; Yutaka Imai
Journal:  Nephrol Dial Transplant       Date:  2012-04-17       Impact factor: 5.992

5.  Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Authors:  Alfred K Cheung; Tara I Chang; William C Cushman; Susan L Furth; Joachim H Ix; Roberto Pecoits-Filho; Vlado Perkovic; Mark J Sarnak; Sheldon W Tobe; Charles R V Tomson; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Johannes F E Mann
Journal:  Kidney Int       Date:  2019-05       Impact factor: 10.612

6.  Blood Pressure, Proteinuria, and Renal Function Decline: Associations in a Large Community-Based Population.

Authors:  Atsushi Hirayama; Tsuneo Konta; Keita Kamei; Kazuko Suzuki; Kazunobu Ichikawa; Shouichi Fujimoto; Kunitoshi Iseki; Toshiki Moriyama; Kunihiro Yamagata; Kazuhiko Tsuruya; Kenjiro Kimura; Ichiei Narita; Masahide Kondo; Koichi Asahi; Issei Kurahashi; Yasuo Ohashi; Tsuyoshi Watanabe
Journal:  Am J Hypertens       Date:  2015-02-11       Impact factor: 2.689

7.  Prevalence of apparent treatment-resistant hypertension among individuals with CKD.

Authors:  Rikki M Tanner; David A Calhoun; Emmy K Bell; C Barrett Bowling; Orlando M Gutiérrez; Marguerite R Irvin; Daniel T Lackland; Suzanne Oparil; David Warnock; Paul Muntner
Journal:  Clin J Am Soc Nephrol       Date:  2013-07-18       Impact factor: 8.237

8.  The Fukuoka Kidney disease Registry (FKR) Study: design and methods.

Authors:  Shigeru Tanaka; Toshiharu Ninomiya; Kiichiro Fujisaki; Hisako Yoshida; Masaharu Nagata; Kosuke Masutani; Masanori Tokumoto; Koji Mitsuiki; Hideki Hirakata; Satoru Fujimi; Yutaka Kiyohara; Takanari Kitazono; Kazuhiko Tsuruya
Journal:  Clin Exp Nephrol       Date:  2016-06-23       Impact factor: 2.801

9.  Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.

Authors:  Alfred K Cheung; Tara I Chang; William C Cushman; Susan L Furth; Fan Fan Hou; Joachim H Ix; Gregory A Knoll; Paul Muntner; Roberto Pecoits-Filho; Mark J Sarnak; Sheldon W Tobe; Charles R V Tomson; Lyubov Lytvyn; Jonathan C Craig; David J Tunnicliffe; Martin Howell; Marcello Tonelli; Michael Cheung; Amy Earley; Johannes F E Mann
Journal:  Kidney Int       Date:  2021-03       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.